First-pass extracted concept

induced pluripotent stem cells

Candidate: concept label4 source documents7 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

iPSCs

Evidence Snippets

Over the past two decades, induced pluripotent stem cells (iPSCs) have reshaped our understanding of ALS pathogenesis and emerged as a promising translational platform for therapy development.

Evidence 1Source 1DOI PubMedprovenance

We then discuss the challenges and opportunities for each model, including the use of induced pluripotent stem cells and incorporation of sensors and actuator modalities to enhance the capabilities of these models.

Evidence 2Source 2DOI PubMedprovenance

This review systematically reviews the research progress of stem cells in the treatment of AS in recent years, focusing on the mechanism of the main cell types such as ... induced pluripotent stem cells (iPSCs)...

Evidence 3Source 3DOI PubMedprovenance

Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells

Evidence 4Source 4provenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 3primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 4primary paperyear unknownPMC

1 evidence snippet 1 linked claim Claim 1

Linked Claims

Claim 1predictive modeling needsupports2026Source 1DOI PubMed

Recent clinical trial setbacks highlight the need for robust translational iPSC models that can better predict therapeutic response.

Claim 2translational platform rolesupports2026Source 1DOI PubMed

Induced pluripotent stem cells are presented as a promising translational platform for ALS therapy development.

Claim 3translation enablersupports2026Source 1DOI PubMed

Large iPSC patient cohorts, quantitative phenotyping, genetically informed patient stratification, and reverse translational research are beginning to close the gap between in vitro discovery and clinical testing in ALS.

Claim 4translation gapsupports2026Source 1DOI PubMed

Effective disease-modifying therapies for ALS remain elusive despite advances in iPSC and three-dimensional modeling.

Claim 5design opportunitysupports2025Source 2DOI PubMed

Use of induced pluripotent stem cells and incorporation of sensors and actuator modalities are presented as opportunities to enhance gut-brain axis microfluidic models.

Claim 6mechanism summarysupports2025Source 3DOI PubMed

The review summarizes MSCs, iPSCs, and EPCs as stem-cell types relevant to atherosclerosis through regulation of lipid metabolism, inhibition of inflammation, repair of vascular endothelium, and stabilization of atherosclerotic plaque.

Claim 7paper objectivesupportsyear unknownSource 4

The paper concerns engineering induced pluripotent stem cells to enable efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells.